<DOC>
	<DOCNO>NCT00036504</DOCNO>
	<brief_summary>The purpose study determine : 1 . If patient take insulin lispro LM metformin well overall control blood sugar patient take long acting insulin comparator metformin . 2 . If difference way two treatment affect blood sugar control meal night . 3 . If difference insulin dose require two treatment . 4 . If difference number time patient experience low blood sugar two treatment . 5 . If difference effect patient 's body weight .</brief_summary>
	<brief_title>Efficacy Safety Twice-Daily Insulin Lispro Low Mixture Compared Once-Daily Long Acting Insulin Comparator Patients Who Have Been Using One More Oral Antihyperglycemic Agents Without Insulin</brief_title>
	<detailed_description>The aim present study compare two treatment - LM twice daily plus metformin two three time daily versus long act insulin comparator daily plus metformin two three time daily - patient type 2 diabetes currently use regimen one oral antihyperglycemic agent . The primary objective study demonstrate , patient type 2 diabetes new insulin , hemoglobin A1c endpoint lower treatment insulin lispro LM twice daily plus metformin treatment long act insulin comparator daily plus metformin . This multicenter , randomize , open-label , crossover study compare twice-daily insulin lispro LM plus two- three-times-daily metformin once-daily long act insulin comparator plus two- three-times-daily metformin patient type 2 diabetes receive one oral antihyperglycemic agent without insulin prior study . Following 8 ( +-2 ) week lead-in period consist treatment NPH daily bedtime plus metformin two three time daily , approximately 100 eligible patient randomize one two sequence group , approximately 50 patient group . One group receive 4 month insulin lispro LM administer immediately morning evening meal plus metformin two three time daily follow 4 month once-daily long act insulin comparator bedtime plus metformin two three time daily . The group receive reverse sequence .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 2 diabetes . At least 30 year old less 80 year old . Using oral agent without insulin 30 day prior ot study . Willing start insulin injection use pen device . Keep patient diary . Undergoing therapy cancer . History renal transplant receive renal dialysis . Have participate interventional medical , surgical , pharmaceutical study ( study medical surgical treatment give ) within 30 day prior entry study . Women breastfeed . Have treat drug within last 30 day receive regulatory approval .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Diabetes mellitus , insulin deficiency , hyperglycemia</keyword>
</DOC>